On June 30, 2026, in San Diego, EirGenix revealed its extensive lineup of biosimilars for HER2-positive breast cancer at BIO 2026. They showcased their all-inclusive contract development and manufacturing organization (CDMO) service platform. The company is focused on expanding its presence in the United States, emphasizing their commitment to providing innovative solutions in the field.